Insider Trading Alert - K, EQR And UTHR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 7, 2014, 153 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $776.50 to $183,196,515.00.

Highlighted Stocks Traded by Insiders:

Kellogg (K) - FREE Research Report

Kellogg W K Foundation Trust, who is 10% Owner at Kellogg, sold 63,300 shares at $65.58 on May 7, 2014. Following this transaction, the 10% Owner owned 72.8 million shares meaning that the stake was reduced by 0.09% with the 63,300-share transaction.

The shares most recently traded at $66.07, up $0.49, or 0.75% since the insider transaction. Historical insider transactions for Kellogg go as follows:

  • 4-Week # shares sold: 250,000
  • 12-Week # shares sold: 656,800
  • 24-Week # shares sold: 656,800

The average volume for Kellogg has been 2.3 million shares per day over the past 30 days. Kellogg has a market cap of $23.5 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 8.19% year-to-date as of the close of trading on Wednesday.

Kellogg Company, together with its subsidiaries, manufactures and markets ready-to-eat cereal and convenience food products primarily in the United States and the United Kingdom. The company operates through U.S. Morning Foods, U.S. Snacks, U.S. The stock currently has a dividend yield of 2.82%. The company has a P/E ratio of 12.5. Currently, there are 2 analysts who rate Kellogg a buy, 4 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on K - FREE

TheStreet Quant Ratings rates Kellogg as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, expanding profit margins, impressive record of earnings per share growth, increase in stock price during the past year and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Kellogg Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Equity Residential (EQR) - FREE Research Report

Strohm Bruce C, who is EVP & General Counsel at Equity Residential, sold 6,806 shares at $60.92 on May 7, 2014. Following this transaction, the EVP & General Counsel owned 20,417 shares meaning that the stake was reduced by 25% with the 6,806-share transaction.

The shares most recently traded at $61.88, up $0.96, or 1.55% since the insider transaction. Historical insider transactions for Equity Residential go as follows:

  • 4-Week # shares sold: 1,615
  • 12-Week # shares sold: 1,615
  • 24-Week # shares sold: 5,427

The average volume for Equity Residential has been 1.9 million shares per day over the past 30 days. Equity Residential has a market cap of $22.0 billion and is part of the financial sector and real estate industry. Shares are up 18.64% year-to-date as of the close of trading on Wednesday.

Equity Residential, a real estate investment trust (REIT), engages in the acquisition, development, and management of multifamily properties in the United States. The stock currently has a dividend yield of 3.2%. The company has a P/E ratio of 290.1. Currently, there are 6 analysts who rate Equity Residential a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EQR - FREE

TheStreet Quant Ratings rates Equity Residential as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Equity Residential Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

United Therapeutics (UTHR) - FREE Research Report

Thompson Tommy G, who is Director at United Therapeutics, sold 400 shares at $107.16 on May 7, 2014. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 400-share transaction.

The shares most recently traded at $108.85, up $1.69, or 1.55% since the insider transaction. Historical insider transactions for United Therapeutics go as follows:

  • 24-Week # shares sold: 1,000

The average volume for United Therapeutics has been 915,800 shares per day over the past 30 days. United Therapeutics has a market cap of $5.1 billion and is part of the health care sector and drugs industry. Shares are down 4.66% year-to-date as of the close of trading on Wednesday.

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. The company has a P/E ratio of 23.7. Currently, there are 5 analysts who rate United Therapeutics a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UTHR - FREE

TheStreet Quant Ratings rates United Therapeutics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full United Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Stocks Waver Amid Progress on U.S.-China Trade; Dow Slips

Stocks Waver Amid Progress on U.S.-China Trade; Dow Slips

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Video: As Trade Worries Subside, Expect a 'Relief Rally' in Stocks

Video: As Trade Worries Subside, Expect a 'Relief Rally' in Stocks